Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

2021134 citationsJournal Articlehybrid Open Access

Authors

Claire Roddie · CRUK Lung Cancer Centre of Excellence

Juliana Dias · Royal Free London NHS Foundation Trust

Maeve O’Reilly

Mahnaz Abbasian · University College London

Amaia Cadiñanos-Garai · University College London

Ketki Vispute · University College London

Leticia Bosshard‐Carter · University College London

Abstract

AUTO1 demonstrates a tolerable safety profile, high remission rates, and excellent persistence in r/r adult B-ALL. Preliminary data support further development of AUTO1 as a stand-alone treatment for r/r adult B-ALL.

Topics & Keywords

CAR-T cell therapy research Advancements in Semiconductor Devices and Circuit Design Nanowire Synthesis and Applications

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 30, pp. 3352-3363

DOI: 10.1200/jco.21.00917

Field-Weighted Citation Impact: 7.69

Command Palette

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Authors

Abstract

Topics & Keywords

Publication Details